TG Therapeutics Inc (TGTX)
19.01
+0.22
(+1.17%)
USD |
NASDAQ |
Jul 05, 16:00
18.99
-0.02
(-0.11%)
After-Hours: 20:00
TG Therapeutics Research and Development Expense (Annual): 76.19M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 76.19M |
| December 31, 2022 | 125.35M |
| December 31, 2021 | 222.58M |
| December 31, 2020 | 165.90M |
| December 31, 2019 | 154.18M |
| December 31, 2018 | 159.39M |
| December 31, 2017 | 102.53M |
| December 31, 2016 | 69.23M |
| December 31, 2015 | 47.71M |
| December 31, 2014 | 40.09M |
| December 31, 2013 | 13.66M |
| December 31, 2012 | 21.03M |
| December 31, 2011 | 0.3273M |
| December 31, 2010 | 0.4958M |
| Date | Value |
|---|---|
| December 31, 2009 | 0.0404M |
| December 31, 2008 | 1.803M |
| December 31, 2007 | 8.536M |
| December 31, 2006 | 6.173M |
| December 31, 2005 | 17.07M |
| December 31, 2004 | 4.153M |
| December 31, 2003 | 1.724M |
| December 31, 2002 | 0.7008M |
| December 31, 2001 | 0.8867M |
| December 31, 2000 | 1.130M |
| December 31, 1999 | 1.10M |
| December 31, 1998 | 3.00M |
| December 31, 1997 | 2.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
76.19M
Minimum
2023
222.58M
Maximum
2021
148.84M
Average
154.18M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Eli Lilly and Co | 9.313B |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 152.38M |
| Insmed Inc | 571.01M |